RESUMEN
Dihydrofolate reductase (DHFR) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase/IMP cyclohydrolase (PurH) play key roles in maintaining folate pools in cells, and are targets of antimicrobial and anticancer drugs. While the activities of bacterial DHFR and PurH on their classical substrates (DHF and 10-CHO-THF, respectively) are known, their activities and kinetic properties of utilisation of 10-CHO-DHF are unknown. We have determined the kinetic properties (kcat/Km) of conversion of 10-CHO-DHF to 10-CHO-THF by DHFR, and to DHF by PurH. We show that DHFR utilises 10-CHO-DHF about one third as efficiently as it utilises DHF. The 10-CHO-DHF is also utilised (as a formyl group donor) by PurH albeit slightly less efficiently than 10-CHO-THF. The utilisation of 10-CHO-DHF by DHFR is ~50 fold more efficient than its utilisation by PurH. A folate deficient Escherichia coli (∆pabA) grows well when supplemented with adenine, glycine, thymine and methionine, the metabolites that arise from the one-carbon metabolic pathway. Notably, when the ∆pabA strain harboured a folate transporter, it grew in the presence of 10-CHO-DHF alone, suggesting that it (10-CHO-DHF) can enter one-carbon metabolic pathway to provide the required metabolites. Thus, our studies reveal that both DHFR and PurH could utilise 10-CHO-DHF for folate homeostasis in E. coli.
Asunto(s)
Escherichia coli/metabolismo , Ácido Fólico/análogos & derivados , Nucleótido Desaminasas/metabolismo , Fosforribosilaminoimidazolcarboxamida-Formiltransferasa/metabolismo , Tetrahidrofolato Deshidrogenasa/metabolismo , Ácido 4-Aminobenzoico , Clonación Molecular , Escherichia coli/genética , Escherichia coli/crecimiento & desarrollo , Ácido Fólico/metabolismo , Deficiencia de Ácido Fólico/genética , Homeostasis , Cinética , Redes y Vías Metabólicas , Nucleótido Desaminasas/genética , Fosforribosilaminoimidazolcarboxamida-Formiltransferasa/genética , Tetrahidrofolato Deshidrogenasa/genéticaRESUMEN
PURPOSE: Mutations in the gene encoding 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC), a bifunctional enzyme that catalyzes the final 2 steps of the purine de novo biosynthetic pathway, were identified in a subject referred for radiation sensitivity testing. Functional studies were performed to determine whether ATIC inhibition was radiosensitizing and, if so, to elucidate the mechanism of this effect and determine whether small molecule inhibitors of ATIC could act as effective radiosensitizing agents. METHODS AND MATERIALS: Both small interfering RNA knockdown and small molecule inhibitors were used to inactivate ATIC in cell culture. Clonogenic survival assays, the neutral comet assay, and γH2AX staining were used to assess the effects of ATIC inhibition or depletion on cellular DNA damage responses. RESULTS: Depletion of ATIC or inhibition of its transformylase activity significantly reduced the surviving fraction of cells in clonogenic survival assays in multiple cancer cell lines. In the absence of ionizing radiation exposure, ATIC knockdown or chemical inhibition activated cell cycle checkpoints, shifting cells to the more radiosensitive G2/M phase of the cell cycle, and depleted cellular adenosine triphosphate but did not result in detectable DNA damage. Cells in which ATIC was knocked down or inhibited and then treated with ionizing radiation displayed increased numbers of DNA double-strand breaks and a delay in the repair of those breaks relative to irradiated, but otherwise untreated, controls. Supplementation of culture media with exogenous adenosine triphosphate ameliorated the DNA repair phenotypes. CONCLUSIONS: These findings implicate ATIC as an effective, and previously unrecognized, target for chemoradiosensitization and, more broadly, suggest that purine levels in cells might have an underappreciated role in modulating the efficiency of DNA damage responses that could be exploited in radiosensitizing strategies.
Asunto(s)
Quimioradioterapia , Roturas del ADN de Doble Cadena , Inhibidores Enzimáticos/uso terapéutico , Mutación del Sistema de Lectura , Transferasas de Hidroximetilo y Formilo/antagonistas & inhibidores , Complejos Multienzimáticos/antagonistas & inhibidores , Proteínas de Neoplasias/antagonistas & inhibidores , Nucleótido Desaminasas/antagonistas & inhibidores , Fármacos Sensibilizantes a Radiaciones/uso terapéutico , Adenosina Trifosfato/administración & dosificación , Puntos de Control del Ciclo Celular/fisiología , Línea Celular Tumoral , Supervivencia Celular/genética , Ensayo Cometa , Daño del ADN , Reparación del ADN , Técnicas de Silenciamiento del Gen , Histonas/análisis , Humanos , Transferasas de Hidroximetilo y Formilo/deficiencia , Transferasas de Hidroximetilo y Formilo/genética , Terapia Molecular Dirigida/métodos , Complejos Multienzimáticos/deficiencia , Complejos Multienzimáticos/genética , Proteínas de Neoplasias/deficiencia , Proteínas de Neoplasias/genética , Nucleótido Desaminasas/deficiencia , Nucleótido Desaminasas/genética , Ensayo de Tumor de Célula MadreRESUMEN
Accumulating evidence indicates that polymorphisms in folate pathway genes play a role in response to methotrexate (MTX) treatment in various diseases. This study explored the influence of these genetic polymorphisms on treatment outcome in pediatric osteosarcoma. Blood and tissue samples from 48 osteosarcoma patients were obtained, and the following polymorphisms were analyzed; SLC19A1 80G>A, DHFR 829C>T, MTHFR 677C>T, MTHFR 1298A>C, and ATIC 347C>G. We evaluated associations between these candidate gene polymorphisms and treatment outcome, including histologic response and event-free and overall survival, of patients treated with high-dose MTX. Patients with ATIC 347C>G exhibited a good histologic response to chemotherapy (odds ratio, 0.13; 95% confidence interval, 0.017-0.978; P=0.048). However, none of these single nucleotide polymorphisms we examined affected event-free survival or overall survival rates of the patients. Even though the role of single nucleotide polymorphisms of ATIC in chemotherapy-induced tumor necrosis has not been investigated yet, the ATIC 347C>G polymorphism may influence the levels of adenosine after MTX treatment, which may affect the histologic response of osteosarcoma. This relationship warrants validation in a larger, prospective cohort study.
Asunto(s)
Transferasas de Hidroximetilo y Formilo/genética , Complejos Multienzimáticos/genética , Nucleótido Desaminasas/genética , Osteosarcoma/tratamiento farmacológico , Osteosarcoma/genética , Polimorfismo de Nucleótido Simple , Adenosina/sangre , Adolescente , Antineoplásicos/uso terapéutico , Niño , Preescolar , Supervivencia sin Enfermedad , Femenino , Humanos , Masculino , Metotrexato/uso terapéutico , Metilenotetrahidrofolato Reductasa (NADPH2)/genética , Osteosarcoma/mortalidad , Proteína Portadora de Folato Reducido/genética , Tasa de Supervivencia , Tetrahidrofolato Deshidrogenasa/genéticaRESUMEN
Methotrexate (MTX) is an important anticancer drug and the most efficient chemotherapy component in primary CNS lymphoma (PCNSL). A typical side effect of intravenous high-dose MTX is the occurrence of confluent CNS white matter changes (WMC). Because MTX directly interferes with methionine metabolism, we analyzed the impact of genetic variants of methionine metabolism on the occurrence of WMC as a model of MTX toxicity. In a retrospective analysis of 68 PCNSL patients treated with MTX-based polychemotherapy with (n = 42) or without (n = 26) intraventricular treatment, 10 genetic variants influencing methionine metabolism were analyzed. Pearson's chi(2) test and multinominal regression analysis were used to define the relevance of these genetic variants for the occurrence of WMC. In this patient sample, the occurrence of WMC was significantly predicted by the TT genotype of methylenetetrahydrofolate reductase c.677C>T (chi(2) = 8.67; p = 0.013; df = 2), the AA genotype of methylenetetrahydrofolate reductase c.1298A>C (chi(2) = 13.5; p = 0.001; df = 2), and the GG genotype of transcobalamin 2 c.776C>G (chi(2) = 19.73; p < 0.001), in addition to male gender (chi(2) = 11.95; p = 0.001). These data strengthen the hypothesis that MTX effects are influenced by methionine metabolism, which may offer new strategies to improve MTX-based therapies.
Asunto(s)
Antimetabolitos Antineoplásicos/efectos adversos , Encéfalo/efectos de los fármacos , Neoplasias del Sistema Nervioso Central/tratamiento farmacológico , Linfoma/tratamiento farmacológico , Metionina/metabolismo , Metotrexato/efectos adversos , Polimorfismo Genético/genética , Encéfalo/metabolismo , Cistationina betasintasa/genética , Femenino , Humanos , Transferasas de Hidroximetilo y Formilo/genética , Masculino , Metionina Sulfóxido Reductasas , Metilenotetrahidrofolato Reductasa (NADPH2)/genética , Proteínas de Microfilamentos , Persona de Mediana Edad , Complejos Multienzimáticos/genética , Nucleótido Desaminasas/genética , Oxidorreductasas/genética , Estudios Prospectivos , Canales Catiónicos TRPM/genética , Tetrahidrofolato Deshidrogenasa/genética , Transcobalaminas/genética , Factores de Transcripción/genéticaRESUMEN
Methotrexate is the gold standard therapy for moderate to severe psoriasis, but there is marked interpersonal variation in its efficacy and toxicity. We hypothesized that in psoriasis patients, specific common polymorphisms in folate, pyrimidine, and purine metabolic enzymes are associated with methotrexate efficacy and/or toxicity. DNA from 203 retrospectively recruited psoriasis patients treated with methotrexate was collected and genotyped by restriction endonuclease digestion or length polymorphism assays. The reduced folate carrier (RFC) 80A allele and the thymidylate synthase (TS) 3'-untranslated region (3'-UTR) 6 bp deletion were associated with methotrexate-induced toxicity (P=0.025 and P=0.025, respectively). RFC 80A and 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC) 347G were associated with methotrexate discontinuation (P=0.048 and P=0.038). The TS 5'-UTR 28 bp 3R polymorphism correlated with poor clinical outcome (P=0.029), however, this was not the case when patients with palmoplantar pustular psoriasis were not included in the analysis. Stronger associations between specific polymorphisms and methotrexate-induced toxicity and discontinuation were found in a subanalysis of patients on methotrexate not receiving folic acid supplementation. We have demonstrated preliminary evidence that specific polymorphisms of enzymes involved in folate, pyrimidine, and purine metabolism could be useful in predicting clinical response to methotrexate in patients with psoriasis.
Asunto(s)
Ácido Fólico/metabolismo , Metotrexato/uso terapéutico , Polimorfismo Genético , Psoriasis/tratamiento farmacológico , Purinas/metabolismo , Pirimidinas/metabolismo , Regiones no Traducidas 5'/genética , Adenosina Desaminasa/genética , Adulto , Haplotipos , Humanos , Transferasas de Hidroximetilo y Formilo/genética , Proteínas de Transporte de Membrana/genética , Metotrexato/efectos adversos , Metilenotetrahidrofolato Reductasa (NADPH2)/genética , Complejos Multienzimáticos/genética , Nucleótido Desaminasas/genética , Psoriasis/genética , Proteína Portadora de Folato Reducido , Timidilato Sintasa/genéticaRESUMEN
A subtraction procedure was developed for identification and isolation of a human gene transcribed in mouse transformant cells. The procedure was based on subtractive enrichment of the products that were amplified by the combination of reverse transcription and polymerase chain reaction from the 3'-untranslated region (3'-UTR) of human poly(A)+ RNA expressed in the mouse transformant cells. To assess the ability and usefulness of the procedure, we attempted to recover the human purH gene from a mouse transformant cell line, which was originally established by functional complementation using the human metaphase chromosome-mediated gene transfer technique from a mouse purH-negative mutant cell line. Using our procedure, a part of the human transcript in the transformant cells was successfully identified and isolated. The full-length cDNA was isolated using the 3'-UTR clone as a probe, and its biological activity was confirmed by introducing it into the mouse purH-negative mutant cells.